Navigation Links
Hill-Rom Reports Second Quarter Financial Results
Date:5/4/2009

=== === === Earnings (Loss) per share - GAAP (1) $1.07 $(6.91) $(6.61) Impairment of goodwill and other intangibles (2) - 7.51 7.51 Liko acquisition inventory step-up - 0.03 0.03 Liko acquisition integration charges - 0.02 0.02 Special charges (3) 0.22 0.20 0.20 Stock modification charge 0.06 - - Loss on extinguishment of debt 0.03 - - Separation costs 0.02 - - ---- --- --- Earnings per share - Adjusted (4) $1.40 $0.85 $1.15 ===== ===== ===== (1) Effective tax rate for last half of fiscal 2009 estimated to be in range of 32 to 34 percent, excluding any future discrete tax items. (2) Does not reflect any true-up of estimated impairment charge in Q3 as amount of any such adjustment is unknown at this time. (3) Special charges in fiscal 2009 includes year-to-date charge of $17.8 million and an estimated additional charge of $2 million related to the finalization of the actions previously announced in January. (4) Adjusted earnings in the above presentation have not been adjusted to remove the effects of discrete period tax adjustments recognized in any of the periods presented. Discrete period tax adjustments are routinely recognized throughout any given year under a variety of circumstances and are highly subjective in nature. For fiscal year 2008, discrete tax benefits totaled $8.3 million ($0.13 per share), while year-to-date discrete tax benefits in fiscal 2009
'/>"/>
SOURCE Hill-Rom Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Hill-Rom to Present at the Bank of America 2009 Health Care Conference
2. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast
3. JCR and Hill-Rom Name First Nurse Scholar-in-Residence
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
6. Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year
7. DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 First Quarter Earnings Webcast
9. Hill-Rom Reports First Quarter Revenue of $350 Million and Announces Further Actions to Address Challenging Economic Environment
10. JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program
11. Hill-Rom Announces First Quarter 2009 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6Health News:Magnetic field measurements of the human heart at room temperature 2Health News:Magnetic field measurements of the human heart at room temperature 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 4Health News:Spice Compounds May Stem Tumor Growth 2
Breaking Medicine Technology:AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Negative Pressure Wound Devices Draw FDA Notice, Advice 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 1EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 2EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 3Community Hospital System Integrates Patient Data with Orion Health 54139 1Community Hospital System Integrates Patient Data with Orion Health 54139 2Community Hospital System Integrates Patient Data with Orion Health 54139 3Re Envision Your Look 3A Dr David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 54137 1Re Envision Your Look 3A Dr David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 54137 2Re Envision Your Look 3A Dr David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 54137 3